Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Loren D. Walensky,1,2
Andrew L. Kung,2,3
Iris Escher,4
Thomas J. Malia,5,6
Scott Barbuto,1
Renee D. Wright,3
Gerhard Wagner,5
Gregory L. Verdine,4*
Stanley J. Korsmeyer1*
Abstract:
BCL-2 family proteins constitute a critical control point forthe regulation of apoptosis. Protein interaction between BCL-2members is a prominent mechanism of control and is mediatedthrough the amphipathic -helical BH3 segment, an essential deathdomain. We used a chemical strategy, termed hydrocarbon stapling,to generate BH3 peptides with improved pharmacologic properties.The stapled peptides, called "stabilized alpha-helix of BCL-2domains" (SAHBs), proved to be helical, protease-resistant,and cell-permeable molecules that bound with increased affinityto multidomain BCL-2 member pockets. A SAHB of the BH3 domainfrom the BID protein specifically activated the apoptotic pathwayto kill leukemia cells. In addition, SAHB effectively inhibitedthe growth of human leukemia xenografts in vivo. Hydrocarbonstapling of native peptides may provide a useful strategy forexperimental and therapeutic modulation of protein-protein interactionsin many signaling pathways.
1 Howard Hughes Medical Institute, 2 Department of Pediatric Hematology/Oncology and Children's Hospital Boston 3 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. 4 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA. 5 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. 6 Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
* To whom correspondence should be addressed. E-mail: stanley_korsmeyer{at}dfci.harvard.edu (S.J.K.) and verdine{at}chemistry.harvard.edu (G.L.V.)
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
Catherine Denicourt and Steven F. Dowdy (3 September 2004) Science305 (5689), 1411.
[DOI: 10.1126/science.1102974] |Summary »|Full Text »|PDF »
REPORTS
Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki, Jef K. De Brabander, Xiaodong Wang, and Patrick G. Harran (3 September 2004) Science305 (5689), 1471.
[DOI: 10.1126/science.1098231] |Abstract »|Full Text »|PDF »|Supporting Online Material »
Direct activation of full-length proapoptotic BAK.
E. S. Leshchiner, C. R. Braun, G. H. Bird, and L. D. Walensky (2013)
PNAS
110, E986-E995
|Abstract »|Full Text »|PDF »
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
R. Haq, S. Yokoyama, E. B. Hawryluk, G. B. Jonsson, D. T. Frederick, K. McHenry, D. Porter, T.-N. Tran, K. T. Love, R. Langer, et al. (2013)
PNAS
110, 4321-4326
|Abstract »|Full Text »|PDF »
On the binding affinity of macromolecular interactions: daring to ask why proteins interact.
P. L. Kastritis and A. M. J. J. Bonvin (2012)
J R Soc Interface
10, 20120835
|Abstract »|Full Text »|PDF »
Inhibition of oncogenic Wnt signaling through direct targeting of {beta}-catenin.
T. N. Grossmann, J. T.- H. Yeh, B. R. Bowman, Q. Chu, R. E. Moellering, and G. L. Verdine (2012)
PNAS
109, 17942-17947
|Abstract »|Full Text »|PDF »
Targeted Disruption of the BCL9/{beta}-Catenin Complex Inhibits Oncogenic Wnt Signaling.
K. Takada, D. Zhu, G. H. Bird, K. Sukhdeo, J.-J. Zhao, M. Mani, M. Lemieux, D. E. Carrasco, J. Ryan, D. Horst, et al. (2012)
Science Translational Medicine
4, 148ra117
|Abstract »|Full Text »|PDF »
Stapling Mimics Noncovalent Interactions of {gamma}-Carboxyglutamates in Conantokins, Peptidic Antagonists of N-Methyl-D-Aspartic Acid Receptors.
R. J. Platt, T. S. Han, B. R. Green, M. D. Smith, J. Skalicky, P. Gruszczynski, H. S. White, B. Olivera, G. Bulaj, and J. Gajewiak (2012)
J. Biol. Chem.
287, 20727-20736
|Abstract »|Full Text »|PDF »
Finding a Panacea among Combination Cancer Therapies.
Polypeptide Modulators of Caspase Recruitment Domain (CARD)-CARD-mediated Protein-Protein Interactions.
Y. Palacios-Rodriguez, G. Garcia-Lainez, M. Sancho, A. Gortat, M. Orzaez, and E. Perez-Paya (2011)
J. Biol. Chem.
286, 44457-44466
|Abstract »|Full Text »|PDF »
Identification of a Novel Mcl-1 Protein Binding Motif.
W. J. Placzek, M. Sturlese, B. Wu, J. F. Cellitti, J. Wei, and M. Pellecchia (2011)
J. Biol. Chem.
286, 39829-39835
|Abstract »|Full Text »|PDF »
Truncation, Randomization, and Selection: GENERATION OF A REDUCED LENGTH c-Jun ANTAGONIST THAT RETAINS HIGH INTERACTION STABILITY.
R. O. Crooks, T. Rao, and J. M. Mason (2011)
J. Biol. Chem.
286, 29470-29479
|Abstract »|Full Text »|PDF »
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.
R. Elkholi, K. V. Floros, and J. E. Chipuk (2011)
Genes & Cancer
2, 523-537
|Abstract »|Full Text »|PDF »
Amphipathic Tail-anchoring Peptide and Bcl-2 Homology Domain-3 (BH3) Peptides from Bcl-2 Family Proteins Induce Apoptosis through Different Mechanisms.
J.-K. Ko, K.-H. Choi, J. Peng, F. He, Z. Zhang, N. Weisleder, J. Lin, and J. Ma (2011)
J. Biol. Chem.
286, 9038-9048
|Abstract »|Full Text »|PDF »
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
M. Liu, C. Li, M. Pazgier, C. Li, Y. Mao, Y. Lv, B. Gu, G. Wei, W. Yuan, C. Zhan, et al. (2010)
PNAS
107, 14321-14326
|Abstract »|Full Text »|PDF »
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.
G. H. Bird, N. Madani, A. F. Perry, A. M. Princiotto, J. G. Supko, X. He, E. Gavathiotis, J. G. Sodroski, and L. D. Walensky (2010)
PNAS
107, 14093-14098
|Abstract »|Full Text »|PDF »
mRNA display selection of a high-affinity, Bcl-XL-specific binding peptide.
N. Matsumura, T. Tsuji, T. Sumida, M. Kokubo, M. Onimaru, N. Doi, H. Takashima, E. Miyamoto-Sato, and H. Yanagawa (2010)
FASEB J
24, 2201-2210
|Abstract »|Full Text »|PDF »
Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency.
R. S. Harrison, N. E. Shepherd, H. N. Hoang, G. Ruiz-Gomez, T. A. Hill, R. W. Driver, V. S. Desai, P. R. Young, G. Abbenante, and D. P. Fairlie (2010)
PNAS
107, 11686-11691
|Abstract »|Full Text »|PDF »
A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.
J. K. Bielicki, H. Zhang, Y. Cortez, Y. Zheng, V. Narayanaswami, A. Patel, J. Johansson, and S. Azhar (2010)
J. Lipid Res.
51, 1496-1503
|Abstract »|Full Text »|PDF »
Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins.
E. F. Lee, A. Fedorova, K. Zobel, M. J. Boyle, H. Yang, M. A. Perugini, P. M. Colman, D. C. S. Huang, K. Deshayes, and W. D. Fairlie (2009)
J. Biol. Chem.
284, 31315-31326
|Abstract »|Full Text »|PDF »
H. Dai, X. W. Meng, S.-H. Lee, P. A. Schneider, and S. H. Kaufmann (2009)
J. Biol. Chem.
284, 18311-18322
|Abstract »|Full Text »|PDF »
Molecular Basis for Bcl-2 Homology 3 Domain Recognition in the Bcl-2 Protein Family: IDENTIFICATION OF CONSERVED HOT SPOT INTERACTIONS.
G. Moroy, E. Martin, A. Dejaegere, and R. H. Stote (2009)
J. Biol. Chem.
284, 17499-17511
|Abstract »|Full Text »|PDF »
Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20.
K. Izumi, E. Kodama, K. Shimura, Y. Sakagami, K. Watanabe, S. Ito, T. Watabe, Y. Terakawa, H. Nishikawa, S. G. Sarafianos, et al. (2009)
J. Biol. Chem.
284, 4914-4920
|Abstract »|Full Text »|PDF »
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents.
B. D. Zeitlin, I. J. Zeitlin, and J. E. Nor (2008)
J. Clin. Oncol.
26, 4180-4188
|Abstract »|Full Text »|PDF »
Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers.
F. A. Sinicrope, R. L. Rego, N. R. Foster, S. N. Thibodeau, S. R. Alberts, H. E. Windschitl, and D. J. Sargent (2008)
Clin. Cancer Res.
14, 4128-4133
|Abstract »|Full Text »|PDF »
Multimodal Targeting of the BCL-2 Family in Cancer.
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt (2008)
Blood
111, 3701-3713
|Abstract »|Full Text »|PDF »
Anti-Apoptosis Mechanisms in Malignant Gliomas.
D. S. Ziegler, A. L. Kung, and M. W. Kieran (2008)
J. Clin. Oncol.
26, 493-500
|Abstract »|Full Text »|PDF »
BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death.
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
M. Nguyen, R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. Murthy Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, et al. (2007)
PNAS
104, 19512-19517
|Abstract »|Full Text »|PDF »
The role of peptide motifs in the evolution of a protein network.
H. Saito, S. Kashida, T. Inoue, and K. Shiba (2007)
Nucleic Acids Res.
35, 6357-6366
|Abstract »|Full Text »|PDF »
The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis.
J.-K. Ko, K.-H. Choi, Z. Pan, P. Lin, N. Weisleder, C.-W. Kim, and J. Ma (2007)
J. Cell Sci.
120, 2912-2923
|Abstract »|Full Text »|PDF »
Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells.
K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush (2007)
Cancer Res.
67, 6368-6375
|Abstract »|Full Text »|PDF »
2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition.
P. S. Schwartz, M. K. Manion, C. B. Emerson, J. S. Fry, C. M. Schulz, I. R. Sweet, and D. M. Hockenbery (2007)
Mol. Cancer Ther.
6, 2073-2080
|Abstract »|Full Text »|PDF »
Targeting Multiple Arms of the Apoptotic Regulatory Machinery.
A Membrane-targeted BID BCL-2 Homology 3 Peptide Is Sufficient for High Potency Activation of BAX in Vitro.
K. J. Oh, S. Barbuto, K. Pitter, J. Morash, L. D. Walensky, and S. J. Korsmeyer (2006)
J. Biol. Chem.
281, 36999-37008
|Abstract »|Full Text »|PDF »
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo..
A. R. Shoemaker, A. Oleksijew, J. Bauch, B. A. Belli, T. Borre, M. Bruncko, T. Deckwirth, D. J. Frost, K. Jarvis, M. K. Joseph, et al. (2006)
Cancer Res.
66, 8731-8739
|Abstract »|Full Text »|PDF »
Targeting protein-protein interactions by rational design: mimicry of protein surfaces.
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. (2006)
Blood
107, 689-697
|Abstract »|Full Text »|PDF »
Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer.
K. W. Yip, J. D. Mocanu, P.Y. B. Au, G. T. Sleep, D. Huang, P. Busson, W.-C. Yeh, R. Gilbert, B. O'Sullivan, P. Gullane, et al. (2005)
Clin. Cancer Res.
11, 8131-8144
|Abstract »|Full Text »|PDF »
Oncogenes as molecular targets in lymphoma.
A. Hachem and R. B. Gartenhaus (2005)
Blood
106, 1911-1923
|Full Text »|PDF »
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.
Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands.
C. L. Day, L. Chen, S. J. Richardson, P. J. Harrison, D. C. S. Huang, and M. G. Hinds (2005)
J. Biol. Chem.
280, 4738-4744
|Abstract »|Full Text »|PDF »
Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy.
J.M. ADAMS, D.C.S. HUANG, A. STRASSER, S. WILLIS, L. CHEN, A. WEI, M. VAN DELFT, J.I. FLETCHER, H. PUTHALAKATH, J. KURODA, et al. (2005)
Cold Spring Harb Symp Quant Biol
70, 469-477
|Abstract »|PDF »
Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in Cancer.